OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC By Ogkologos - April 14, 2026 151 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the stage 1 of the phase III PRESERVE-003 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Cancer Patients May Soon Be Able to Get an Entire Course... January 21, 2020 Reunión anual de la American Society of Clinical Oncology de 2022:... June 5, 2022 European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening... January 22, 2026 Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer February 10, 2022 Load more HOT NEWS Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC... A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target... Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... Getting Help for Sexual Health Problems When You Have Head and...
